PREVENAR ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
65原発性免疫不全症候群4

65. 原発性免疫不全症候群


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01075438
(ClinicalTrials.gov)
March 201024/2/2010Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia PatientsDescriptive Immunogenicity of 2 Doses of Pneumococcal 7-valent Conjugate Vaccine (Prevenar®, Wyeth Lederle) Followed by Pneumococcal Polysaccharide Vaccine (Pneumovax® Aventis Pasteur MSD) in Ataxia-telangiectasia PatientsAtaxia TelangiectasiaBiological: Prevenar® (7-valent pneumococcal conjugate vaccine);Biological: Pneumovax® (pneumococcal polysaccharide vaccine)Sheba Medical CenterNULLNot yet recruiting2 Years25 YearsBoth20N/AIsrael
2EUCTR2007-003235-23-FR
(EUCTR)
09/01/200923/10/2008Essai randomisé multicentrique de phase II d'évaluation immunologique d'une stratégie vaccinale de type prime boost associant une administration du vaccin conjugué anti-pneumococcique à S0 suivie de l'injection du vaccin polysaccharidique à S4 comparé à l'administration du vaccin polysaccharidique seul à S4 chez des patients ayant un déficit immunitaire commun variable - Evaluation d'une stratégie vaccinale anti-pneumococcique chez des patients aynt un DICVEssai randomisé multicentrique de phase II d'évaluation immunologique d'une stratégie vaccinale de type prime boost associant une administration du vaccin conjugué anti-pneumococcique à S0 suivie de l'injection du vaccin polysaccharidique à S4 comparé à l'administration du vaccin polysaccharidique seul à S4 chez des patients ayant un déficit immunitaire commun variable - Evaluation d'une stratégie vaccinale anti-pneumococcique chez des patients aynt un DICV Déficit immunitaire commun variable
MedDRA version: 9.1;Level: LLT;Classification code 10010112;Term: Common variable immunodeficiency
Trade Name: PNEUMO 23
Trade Name: PREVENAR
InsermNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2France
3NCT00656409
(ClinicalTrials.gov)
June 20067/4/2008Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)Ataxia Telangiectasia (AT)Drug: Conjugated pneumococcal vaccine (Prevenar)Institute of Child HealthGreat Ormond Street Hospital for Children NHS Foundation TrustCompleted2 YearsN/ABoth30Phase 3United Kingdom
4EUCTR2005-004122-70-GB
(EUCTR)
15/11/200512/09/2005Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine. - Immunogenicity of Prevenar in Ataxia telangiectasiaImmunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine. - Immunogenicity of Prevenar in Ataxia telangiectasia Ataxia Telangiectasia (AT) is a genetic condition in which there is a deficiency of the immune system with excessive susceptibility to pneumonia and other infections.Trade Name: PrevenarGreat Ormond Street HospitalNULLNot Recruiting Female: yes
Male: yes
30 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom